Background Gastric cancer (GC) is considered one of the most lethal malignancies worldwide, which is accompanied by a poor prognosis. Although reports regarding the importance of cancer stem cell (CSC) markers in gastric cancer progression have rapidly developed over the last few decades, their clinicopathological and prognostic values in gastric cancer still remain inconclusive. Therefore, the current meta-analysis aimed to quantitatively re-evaluate the association of CSC markers expression, overall and individually, with GC patients’ clinical and survival outcomes. Methods Literature databases including PubMed, Scopus, ISI Web of Science, and Embase were searched to identify the eligible articles. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were recorded or calculated to determine the relationships between CSC markers expression positivity and overall survival (OS), disease-free survival (DFS)/relapse-free survival (RFS), disease-specific survival (DSS)/ cancer-specific survival (CSS), and clinicopathological features. Results We initially retrieved 4,425 articles, of which a total of 66 articles with 89 studies were considered as eligible for this meta-analysis, comprising of 11,274 GC patients. Overall data analyses indicated that the overexpression of CSC markers is associated with TNM stage (OR = 2.19, 95% CI 1.84–2.61, P = 0.013), lymph node metastasis (OR = 1.76, 95% CI 1.54–2.02, P < 0.001), worse OS (HR = 1.65, 95% CI 1.54–1.77, P < 0.001), poor CSS/DSS (HR = 1.69, 95% CI 1.33–2.15, P < 0.001), and unfavorable DFS/RFS (HR = 2.35, 95% CI 1.90–2.89, P < 0.001) in GC patients. However, CSC markers expression was found to be slightly linked to tumor differentiation (OR = 1.25, 95% CI 1.01–1.55, P = 0.035). Sub-analysis demonstrated a significant positive relationship between most of the individual markers, specially Gli-1, Oct-4, CD44, CD44V6, and CD133, and clinical outcomes as well as the reduced survival, whereas overexpression of Lgr-5, Nanog, and sonic hedgehog (Shh) was not found to be related to the majority of clinical outcomes in GC patients. Conclusion The expression of CSC markers is mostly associated with worse outcomes in patients with GC, both overall and individual. The detection of a combined panel of CSC markers might be appropriate as a prognostic stratification marker to predict tumor aggressiveness and poor prognosis in patients with GC, which probably results in identifying novel potential targets for therapeutic approaches.
An efficient and safe delivery system for the transfection of CRISPR plasmid (p/CRISPR) into target cells can open new avenues for the treatment of various diseases. Herein, we design a novel nonvehicle by integrating an arginine-disulfide linker with low-molecular-weight PEI (PEI1.8k) for the delivery of p/CRISPR. These PEI1.8k-Arg nanoparticles facilitate the plasmid release and improve both membrane permeability and nuclear localization, thereby exhibiting higher transfection efficiency compared to native PEI1.8k in the delivery of nanocomplexes composed of PEI1.8k-Arg and p/CRISPR into conventional cells (HEK 293T). This nanovehicle is also able to transfect p/CRISPR in a wide variety of cells, including hard-to-transfect primary cells (HUVECs), cancer cells (HeLa), and neuronal cells (PC-12) with nearly 5–10 times higher efficiency compared to the polymeric gold standard transfection agent. Furthermore, the PEI1.8k-Arg nanoparticles can edit the GFP gene in the HEK 293T-GFP reporter cell line by delivering all possible forms of CRISPR/Cas9 system (e.g. plasmid encoding Cas9 and sgRNA targeting GFP, and Cas9/sgRNA ribonucleoproteins (RNPs) as well as Cas9 expression plasmid and in vitro-prepared sgRNA) into HEK 293T-GFP cells. The successful delivery of p/CRISPR into local brain tissue is also another remarkable capability of these nanoparticles. In view of all the exceptional benefits of this safe nanocarrier, it is expected to break new ground in the field of gene editing, particularly for therapeutic purposes.
Background: Non-coding RNAs are a cluster of RNAs that do not encode functional proteins, and involve infrastructural and regulatory types, which transfer RNAs (tRNAs) belong to former and small RNAs (sRNA) to the latter one. Recently, tRNA-derived small RNAs (tDRs) were discovered among small non-coding RNA, as the newly discovered regulatory small RNA. It plays a role in pathological and physiological processes, which is frequently dysregulated in gene expression regulation. tsRNAs can be bounded to argonaute proteins and piwi proteins such as miRNAs and piRNAs sequentially. In addition, it can interact with DNA and histone methylation machinery Results: In initial searching, 2744 unique articles were identified by bio electronically search of following databases: PubMed, Embase, Web of Science, Scopus, and google scholar up to 25 February 2020. Finally, after Full-text assessment 48 related article to gene expression profiling tsRNA in cancer were achieved. Conclusions: In this systematic review, we summarized the most recent findings related to the expression of tsRNAs in 17 cancer types. We suggested that tsRNA in cancer field attracted the researchers' focus and effectively facilitated diagnostic and therapy approaches.
Background: Non-coding RNAs are a cluster of RNAs that do not encode functional proteins, and involve infrastructural and regulatory types, which transfer RNAs (tRNAs) belong to former and small RNAs (sRNA) to the latter one. Recently, tRNA-derived small RNAs (tDRs) were discovered among small non-coding RNA, as the newly discovered regulatory small RNA. It plays a role in pathological and physiological processes, which is frequently dysregulated in gene expression regulation. tsRNAs can be bounded to argonaute proteins and piwi proteins such as miRNAs and piRNAs sequentially. In addition, it can interact with DNA and histone methylation machinery Results: In initial searching, 2744 unique articles were identified by bio electronically search of following databases: PubMed, Embase, Web of Science, Scopus, and google scholar up to 25 February 2020. Finally, after Full-text assessment 48 related article to gene expression profiling tsRNA in cancer were achieved. Conclusions: In this systematic review, we summarized the most recent findings related to the expression of tsRNAs in 17 cancer types. We suggested that tsRNA in cancer field attracted the researchers' focus and effectively facilitated diagnostic and therapy approaches. There is little consensus over tRF production mechanism, and dicer-dependent cleavage of mature tRNAs has been suggested [11]. Dysregulation of tsRNAs could interfere in the gene expression in pre/post transcriptional and protein translation. Furthermore, researchers target the tsRNA via gene repression of mRNAs, reported construct silencing, translation inhibition, cell proliferation modulation, exonuclease mRNAs Xrn2-mediated degradation, Ybx1 protein displacement, and sense-induced trans-silencing [12]. Moreover, they have been engaged in cellular and pathophysiological tools, concerning porphyrin biosynthesis, reverse transcription, cell proliferation, differentiation, viability, cell signalling, control of viral replication, and utterly in disease ranging from metabolic disorders and neuro degenerative disease to various types of cancer [13-19]. At first, in 2009, small RNA sequencing data was recognized as tsRNA in prostate cancer [20]. Then, the scientists analyzed more samples, which were abundant in small RNA [21]. They declared that, this biomarker could be potentially applied in many cancer types as a screening and even be targeted for therapy. Moreover, tsRNA is essential in cell cycle proliferation and propagation as well as playing a significant role in tumorigenesis either oncogenic or tumor-suppressor functions [22]. Besides, induction and dysregulation of a set of hypoxia related tsRNAs and also tsRNA suppressive factors in Notch signaling pathway can help in maintenance and metastasis of cancer stem cell [23, 24]. Unfortunately, the exact pathway of tsRNA in cancer has not been clarified yet and we design the schematic of tRNA-derived small RNAs biogenesis in Fig. 1. In this systematic review, we summarized the frequency and function of tsRNAs in different cancer types. Met...
Background: less studies have been done on bone cancers which are complex despite lower incidance. Hydatidosis is a parasitic disease that may influence host immunity by mimicking cancer cells antigens. So, this study aimed to elavuate the similarity of the immunogenic antigens between hydatid cyst and different bone cancers.Method: Cyst wall of hydatid cysts were collected and their antigens were separated with SDS-PAGE gel electrophoresis (SDS-PAGE). Serum samples obtained from patients with bone cancers and the anitigenicity of isolated anitgens were evaluated inwith E. granulosus( Larval form )infection and healthy individuals using western-blot approaches. Results: The crude extract of the laminated layer showed two specific antigens, 53 KDa and 70 KDa, after stainging the membrane with Coomassie blue. Both antigens reacted with the serum of different bone cancers but only the 53 KDa band reacted with all sera.Conclusion: It seems people with bone tumours may have extra antibodies in their serum comparing to healthy and hydatidosis which may be an autoantibodies; and the presence of this antibody against 70 KDa band protein in sera of patients with various types of bone cancers, may be helpful in diagnostic test or designing of preventive approaches in future.
Background Recent reports suggested that circulating exosomal microRNAs (exomiRs) may serve as non-invasive prediction biomarkers in gastrointestinal (GI) cancers, yet their clinicopathological and prognostic values need to be more clarified. Hence, the present meta-analysis was aimed to quantitatively assess the evidence regarding the association between circulating exomiRs and prognosis in GI cancer patients. Methods A comprehensive search was carried out in prominent literature databases, including PubMed, ISI Web of Science, Scopus, and Embase. Odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (CIs) were gathered to evaluate the strength of the association. The quality assessment was investigated through the Newcastle-Ottawa Scale (NOS) and publication bias via Eggers’ test and funnel plots. Results A total of 47 studies, comprising of 4881 patients, were considered eligible for this meta-analysis. Both up-regulated and down-regulated circulating exomiRs are significantly associated with differentiation (HR = 1.353, P = 0.015; HR = 1.504, P = 0.016), TNM stage (HR = 2.058, P < 0.001; HR = 2.745, P < 0.001), lymph node metastasis (HR = 1.527, P = 0.004; HR = 2.009, P = 0.002), distant metastasis (HR = 2.006, P < 0.001; HR = 2.799, P = 0.002), worse overall survival (OS) (HR = 2.053, P < 0.001; HR = 1.789, P = 0.001) and poorer disease/relapse/progression-free survival (DFS/RFS/PFS) (HR = 2.086, P < 0.001; HR = 1.607, P = 0.001) in GI cancer patients, respectively. In addition, subgroup analyses based on seven subcategories indicated the robustness of the association. The majority of findings were lack of publication bias except for the association between up-regulated exomiRs and OS or DFS/RFS/PFS and for the down-regulated exomiRs and TNM stage. Conclusion This study supports that up- and down-regulated circulating exomiRs are associated with poorer survival outcomes and could be served as potential prognostic biomarkers in GI cancers. Given the limitations of the current findings, such as significant heterogeneity, more investigations are needed to fully clarify the exomiRs prognostic role.
Over the years, regarding great progresses in knowledge of immunology and neuroscience, the treatment of multiple sclerosis (MS) has been changed. The earlier strategies were focused mainly on T lymphocytes as pioneer cells responsible to inflammatory damage in the central nervous system lesions, whereas B cells, plasma cells and antibodies are also found in the active nerve lesions in MS patients. Despite the accumulating evidence, the role of Myelin basic protein (MBP) antibodies in progression of lesions in nervous system is not completely clear yet. In this regard, here, we present data on B cells and antibody level after MBP immunization of MS mice model. Recombinant fusion protein harboring Myelin basic protein peptide (amino acids 83–99) and CFP was produced in E. coli and purified with chromatography. Then, the C57BL / 6 mice were immunized by rMBP-CFP. Antibody-based assay was used to quantify the level of reactivity to the MBP in mice serum. Subsequently, humoral immunity was analyzed by immunohistochemistry (IHC), ELISA, and Flow cytometry. Our data indicated an increase in autoreactive B cells and MBP specific antibodies after immunization. IHC analysis revealed an increasing penetration rate of immune cells and the nerve lesions development in the nervous system following increasing in MBP antibody titers.This study represented data to support this idea that reactive B cells and antibodies to MBP may contribute to MS pathogenesis. Hence, targeting of these autoreactive B cells and antibodies can be used as potential tools in treatment of MS patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.